A survey study of self‐reported comorbidities among adults with vitiligo in the United States
Abstract Background Vitiligo is an autoimmune disorder in which the immune system targets melanocytes, manifesting in patches of lost skin pigmentation. Objectives To characterize the occurrence of autoimmune/autoinflammatory and/or nonautoimmune comorbid conditions in patients with vitiligo. Method...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.111 |
| _version_ | 1797814000700882944 |
|---|---|
| author | Khaled Ezzedine Kathryn P. Anastassopoulos Kavita Gandhi Shoshana R. Daniel Yuji Yamaguchi Vanja Sikirica Amit G. Pandya |
| author_facet | Khaled Ezzedine Kathryn P. Anastassopoulos Kavita Gandhi Shoshana R. Daniel Yuji Yamaguchi Vanja Sikirica Amit G. Pandya |
| author_sort | Khaled Ezzedine |
| collection | DOAJ |
| description | Abstract Background Vitiligo is an autoimmune disorder in which the immune system targets melanocytes, manifesting in patches of lost skin pigmentation. Objectives To characterize the occurrence of autoimmune/autoinflammatory and/or nonautoimmune comorbid conditions in patients with vitiligo. Methods Adults representative of the 2017 US Census population were recruited for an online, cross‐sectional survey. Based on responses to vitiligo screening questions, participants were categorized into one of three groups: diagnosed vitiligo, undiagnosed vitiligo and no vitiligo. Participants reported clinical‐diagnosed conditions from prespecified lists of 13 autoimmune/autoinflammatory conditions and 21 nonautoimmune conditions. Results A total of 40,888 adults participated in the online survey; 315 (0.8%) were categorized as diagnosed vitiligo, 249 (0.6%) as undiagnosed vitiligo and 40,325 (98.6%) as no vitiligo. The percentage of participants with at least one autoimmune/autoinflammatory comorbidity was 2.65 times greater in the diagnosed vitiligo group than in the no vitiligo group. Psoriasis, rheumatoid arthritis and multiple sclerosis had the greatest difference in the percentage of participants between the diagnosed vitiligo and no vitiligo groups. The percentage of participants with nonautoimmune comorbidities was higher in the diagnosed vitiligo group than in the no vitiligo group. Vision changes, arthritis, back pain, anxiety, depression and sudden hearing loss had the greatest difference in the percentage of participants between the diagnosed vitiligo group and the no vitiligo group. Conclusions This large survey found that both autoimmune/autoinflammatory and nonautoimmune conditions were more common among adults with vitiligo. The greater percentage of autoimmune/autoinflammatory conditions in participants with vitiligo suggests that screening for such comorbidities may be beneficial and may indicate important opportunities for early intervention. |
| first_indexed | 2024-03-13T08:01:04Z |
| format | Article |
| id | doaj.art-4d96663026df45e7b6b690ad6d9273a7 |
| institution | Directory Open Access Journal |
| issn | 2768-6566 |
| language | English |
| last_indexed | 2024-03-13T08:01:04Z |
| publishDate | 2023-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | JEADV Clinical Practice |
| spelling | doaj.art-4d96663026df45e7b6b690ad6d9273a72023-06-01T15:13:20ZengWileyJEADV Clinical Practice2768-65662023-06-012230030510.1002/jvc2.111A survey study of self‐reported comorbidities among adults with vitiligo in the United StatesKhaled Ezzedine0Kathryn P. Anastassopoulos1Kavita Gandhi2Shoshana R. Daniel3Yuji Yamaguchi4Vanja Sikirica5Amit G. Pandya6Department of Dermatology Hôpital Henri Mondor Créteil FranceMarket Access Consulting Labcorp Drug Development Gaithersburg Maryland USAPatient & Health Impact, Pfizer Collegeville Pennsylvania USAMarket Access Consulting Labcorp Drug Development Gaithersburg Maryland USAInflammation & Immunology Research Unit, Pfizer Collegeville Pennsylvania USAPatient & Health Impact, Pfizer Collegeville Pennsylvania USADepartment of Dermatology Palo Alto Foundation Medical Group Sunnyvale California USAAbstract Background Vitiligo is an autoimmune disorder in which the immune system targets melanocytes, manifesting in patches of lost skin pigmentation. Objectives To characterize the occurrence of autoimmune/autoinflammatory and/or nonautoimmune comorbid conditions in patients with vitiligo. Methods Adults representative of the 2017 US Census population were recruited for an online, cross‐sectional survey. Based on responses to vitiligo screening questions, participants were categorized into one of three groups: diagnosed vitiligo, undiagnosed vitiligo and no vitiligo. Participants reported clinical‐diagnosed conditions from prespecified lists of 13 autoimmune/autoinflammatory conditions and 21 nonautoimmune conditions. Results A total of 40,888 adults participated in the online survey; 315 (0.8%) were categorized as diagnosed vitiligo, 249 (0.6%) as undiagnosed vitiligo and 40,325 (98.6%) as no vitiligo. The percentage of participants with at least one autoimmune/autoinflammatory comorbidity was 2.65 times greater in the diagnosed vitiligo group than in the no vitiligo group. Psoriasis, rheumatoid arthritis and multiple sclerosis had the greatest difference in the percentage of participants between the diagnosed vitiligo and no vitiligo groups. The percentage of participants with nonautoimmune comorbidities was higher in the diagnosed vitiligo group than in the no vitiligo group. Vision changes, arthritis, back pain, anxiety, depression and sudden hearing loss had the greatest difference in the percentage of participants between the diagnosed vitiligo group and the no vitiligo group. Conclusions This large survey found that both autoimmune/autoinflammatory and nonautoimmune conditions were more common among adults with vitiligo. The greater percentage of autoimmune/autoinflammatory conditions in participants with vitiligo suggests that screening for such comorbidities may be beneficial and may indicate important opportunities for early intervention.https://doi.org/10.1002/jvc2.111comorbiditiessurveyUnited Statesvitiligo |
| spellingShingle | Khaled Ezzedine Kathryn P. Anastassopoulos Kavita Gandhi Shoshana R. Daniel Yuji Yamaguchi Vanja Sikirica Amit G. Pandya A survey study of self‐reported comorbidities among adults with vitiligo in the United States JEADV Clinical Practice comorbidities survey United States vitiligo |
| title | A survey study of self‐reported comorbidities among adults with vitiligo in the United States |
| title_full | A survey study of self‐reported comorbidities among adults with vitiligo in the United States |
| title_fullStr | A survey study of self‐reported comorbidities among adults with vitiligo in the United States |
| title_full_unstemmed | A survey study of self‐reported comorbidities among adults with vitiligo in the United States |
| title_short | A survey study of self‐reported comorbidities among adults with vitiligo in the United States |
| title_sort | survey study of self reported comorbidities among adults with vitiligo in the united states |
| topic | comorbidities survey United States vitiligo |
| url | https://doi.org/10.1002/jvc2.111 |
| work_keys_str_mv | AT khaledezzedine asurveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT kathrynpanastassopoulos asurveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT kavitagandhi asurveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT shoshanardaniel asurveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT yujiyamaguchi asurveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT vanjasikirica asurveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT amitgpandya asurveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT khaledezzedine surveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT kathrynpanastassopoulos surveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT kavitagandhi surveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT shoshanardaniel surveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT yujiyamaguchi surveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT vanjasikirica surveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates AT amitgpandya surveystudyofselfreportedcomorbiditiesamongadultswithvitiligointheunitedstates |